BioAtla (BCAB) Receivables - Other (2025 - 2026)

BioAtla's (BCAB) quarterly Receivables - Other came in at $4.5 million in Q2 2026, little changed quarter-over-quarter from $4.5 million in Q1 2026.

Analysis

BioAtla (BCAB) Receivables - Other (2025 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Receivables - Other for 2 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Receivables - Other changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Jun 2026 stood at $4.5 million (changed N/A YoY), and the FY2025 full-year result was $3.1 million, changed N/A from the prior year.
Receivables - Other was little changed at $4.5 million in Q2 2026 per BCAB's latest filing, from $4.5 million in the prior quarter.
Across five years, Receivables - Other topped out at $4.5 million in Q1 2026 and bottomed at $3.1 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.69 Bn	192.70 Bn	7.24 Bn
2	Gilead Sciences	179.87 Bn	176.70 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.73 Bn	122.88 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.70 Bn	73.71 Bn	3.93 Bn
5	Argenx Se	60.40 Bn	55.21 Bn	1.37 Bn
6	Moderna	54.28 Bn	49.14 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.02 Bn	29.71 Bn	992.69 Mn
8	Biogen	31.93 Bn	30.64 Bn	1.96 Bn
9	Roivant Sciences	29.27 Bn	29.27 Bn	1.16 Mn
10	BioAtla	2.33 Mn	2.33 Mn	-

Historic Data

Download Data